Literature DB >> 23766360

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.

Paolo Michieli, Cristina Basilico, Selma Pennacchietti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23766360     DOI： 10.1158/1078-0432.CCR-13-1534

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.

Authors:  H Kaspar Binz; Talitha R Bakker; Douglas J Phillips; Andreas Cornelius; Christof Zitt; Thomas Göttler; Gabriel Sigrist; Ulrike Fiedler; Savira Ekawardhani; Ignacio Dolado; Johan Abram Saliba; Gaby Tresch; Karl Proba; Michael T Stumpp
Journal:  MAbs       Date:  2017 Nov/Dec       Impact factor: 5.857

2.  Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

Authors:  Mark N Stein; Kim M Hirshfield; Hua Zhong; Eric A Singer; Siraj M Ali; Shridar Ganesan
Journal:  Eur Urol       Date:  2014-10-27       Impact factor: 20.096

3.  Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.

Authors:  Brent M Kuenzi; Lily L Remsing Rix; Fumi Kinose; Jodi L Kroeger; Jeffrey E Lancet; Eric Padron; Uwe Rix
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 4.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

Authors:  Qinlian Jiao; Lei Bi; Yidan Ren; Shuliang Song; Qin Wang; Yun-Shan Wang
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.